TY - JOUR
T1 - Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy
T2 - A global, observational study
AU - Joerg, Vincent
AU - Scheiner, Bernhard
AU - D'Alessio, Antonio
AU - Fulgenzi, Claudia A.M.
AU - Schönlein, Martin
AU - Kocheise, Lorenz
AU - Lohse, Ansgar W.
AU - Huber, Samuel
AU - Wege, Henning
AU - Kaseb, Ahmed
AU - Wang, Yinghong
AU - Mathew, Antony
AU - Kuang, Andrew
AU - Muzaffar, Mahvish
AU - Abugabal, Yehia I.
AU - Chamseddine, Shadi
AU - Phen, Samuel
AU - Cheon, Jaekyung
AU - Lee, Pei Chang
AU - Balcar, Lorenz
AU - Krall, Anja
AU - Ang, Celina
AU - Wu, Linda
AU - Saeed, Anwaar
AU - Huang, Yi Hsiang
AU - Bengsch, Bertram
AU - Rimassa, Lorenza
AU - Weinmann, Arndt
AU - Stauber, Rudolf
AU - Korolewicz, James
AU - Pinter, Matthias
AU - Singal, Amit G.
AU - Chon, Hong Jae
AU - Pinato, David J.
AU - Schulze, Kornelius
AU - von Felden, Johann
N1 - Publisher Copyright:
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
PY - 2023/11
Y1 - 2023/11
N2 - Background: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. However, evidence on the efficacy and safety of the novel treatment standard in patients with prior exposure to systemic treatment is scarce. The aim of this global, multicenter, observational study was to evaluate the efficacy and safety of AB in patients after previous systemic therapy. Methods: We screened our global, multicenter, prospectively maintained registry database for patients who received any systemic therapy before AB. The primary end point was overall survival; secondary end points were time-to-progression, progression-free survival, objective response rate, and safety (rate and severity of adverse events). Results: Among 493 patients who received AB for unresectable HCC, 61 patients received prior systemic therapy and were included in this analysis. The median age of the study population was 66 years, with 91.8% males. Predominant risk factors for HCC were viral hepatitis (59%) and alcohol (23%). Overall survival for AB was 16.2 (95% CI, 14.5-17.9) months, time-to-progression and progression-free survival were 4.1 (95% CI, 1.5-6.6) and 3.1 (95% CI, 1.1-5.1) months, respectively. The objective response rate was 38.2% (7.3% with complete and 30.9% with partial response). Overall survival was not influenced by treatment line (2nd vs. > 2nd) or previous systemic treatment modality (tyrosine kinase inhibitors vs. immune checkpoint inhibitors). Treatment-related adverse events of all grades according to Common Terminology Criteria for Adverse Events were documented in 42.6% of patients, with only 13.1% of grade ≥ 3, including one death. Conclusion: In this observational study, AB emerges as a safe and efficacious treatment option in patients with HCC previously treated with other systemic therapy.
AB - Background: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. However, evidence on the efficacy and safety of the novel treatment standard in patients with prior exposure to systemic treatment is scarce. The aim of this global, multicenter, observational study was to evaluate the efficacy and safety of AB in patients after previous systemic therapy. Methods: We screened our global, multicenter, prospectively maintained registry database for patients who received any systemic therapy before AB. The primary end point was overall survival; secondary end points were time-to-progression, progression-free survival, objective response rate, and safety (rate and severity of adverse events). Results: Among 493 patients who received AB for unresectable HCC, 61 patients received prior systemic therapy and were included in this analysis. The median age of the study population was 66 years, with 91.8% males. Predominant risk factors for HCC were viral hepatitis (59%) and alcohol (23%). Overall survival for AB was 16.2 (95% CI, 14.5-17.9) months, time-to-progression and progression-free survival were 4.1 (95% CI, 1.5-6.6) and 3.1 (95% CI, 1.1-5.1) months, respectively. The objective response rate was 38.2% (7.3% with complete and 30.9% with partial response). Overall survival was not influenced by treatment line (2nd vs. > 2nd) or previous systemic treatment modality (tyrosine kinase inhibitors vs. immune checkpoint inhibitors). Treatment-related adverse events of all grades according to Common Terminology Criteria for Adverse Events were documented in 42.6% of patients, with only 13.1% of grade ≥ 3, including one death. Conclusion: In this observational study, AB emerges as a safe and efficacious treatment option in patients with HCC previously treated with other systemic therapy.
UR - https://www.scopus.com/pages/publications/85183386730
U2 - 10.1097/HC9.0000000000000302
DO - 10.1097/HC9.0000000000000302
M3 - Article
SN - 2471-254X
VL - 7
JO - Hepatology Communications
JF - Hepatology Communications
IS - 11
M1 - e0302
ER -
